Wednesday, 9 September 2009

Check in whose pocket the author is ? before you read them..

Would you buy an used car from this gentleman?

In an article published by Medscape CME by Louis Kuritzky MD of Gainesville, Florida, USA, he begins the premise by saying that:

All type 2 DM patients at diagnosis must be started on Metformin and titrated to bring the blood sugar down.

Because of disease progression and beta cell function loss over time, mot patients will require insulin therapy.

I didn’t wish to further read this article.

The article is titled

Overcoming Barriers to Insulin Treatment

Dated 27th august 2009

Hasn’t he read the recent article from Italy about putting people newly diagnosed with Type 2 diabetes on a Mediterranean diet and about 60 per cent were still doing well few years later on?

If most people will require Insulin therapy, what does it portend for the people from poor countries like Cambodia? Is he just talking about his population, obese and overweight people who live in a country with some of the worst food in terms of chemical content?

I decided to look up this guy, who is Louis Kuritzky MD

Clinical Assistant Professor, that usually means that he is not an academic but has an attachment to the university, and that he is in private practice of medicine.

His clinical (honorary) attachment is to the department of Community Health. Thus he is not an expert on Insulin therapy..

Here comes the icing on the cake.

This Dr Kuritzky is on the advisory boards for Eli Lilly and Novo Nordisk and Sanofi-Aventis; not just one company that makes Insulin but three..

Would you continue to read this article? You can if you wish, I rather not buy even an used car from him, let alone trust the future of my patients to his advice… Thank You..

If you want more information on this guy, just google it and you will find that:

He is a Family Practitioner/General Practitioner. Dr. Kuritzky is a consultant for GlaxoSmithKline and is on the speaker's bureau of GlaxoSmithKline, 3M, Wyeth-Ayerst, Pfizer, Novartis, Bristol-Myers Squibb, AstraZeneca, Jones Pharma, and Boehringer Ingelheim.

Ah Well!